Accessibility of abciximab to megakaryocytes and endothelial cells in the bone marrow compartment: studies on a patient receiving antithrombotic therapy

This publication has 14 references indexed in Scilit:

• Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1999
• Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and α _v β ₃ Integrins
  Circulation, 1998
• Vitronectin Receptor (α _v β ₃ ) Mediates Platelet Adhesion to the Luminal Aspect of Endothelial Cells
  Circulation, 1997
• Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
  Journal of Clinical Investigation, 1997
• Ultrastructural analysis of the distribution of the vitronectin receptor (α _v β ₃ ) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the α‐granule membrane
  British Journal of Haematology, 1997
• Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy
  Circulation, 1997
• Abciximab-Associated Profound Thrombocytopenia: Therapy With Immunoglobulin and Platelet Transfusion
  The American Journal of Cardiology, 1996
• Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into Perspective
  The American Journal of Cardiology, 1996
• Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa
  Blood Coagulation & Fibrinolysis, 1993
• A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.
  Journal of Clinical Investigation, 1985